Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ( with suitable contraception) over 18 years of age 75~* OPMD confirmed by genetic diagnosis ( gene mutation PABPN1 by triplet expansion GCG)~* OPMD with ptosis~* Obtaining informed consent signed~Exclusion Criteria:~* Evolutionary contagious infectious pathology~* Inflammatory diseases~* Any other neuromuscular disease~* Malignant tumor pathology of history~* Renal impairment ( creatinine clearance \< 60ml / min)~* Hepatic insufficiency~* Pregnant woman confirmed by a dosing B-HCG or lactating~* Inability to perform a muscle biopsy~* Preparation of myoblasts uncommitted to step 2nd release~* Inability to follow up to 36 months~* Refusal to sign the consent form~* No Social Security

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Myoblast autologous graft (Type: EXPERIMENTAL): 30 million autologous myoblasts in 6 intramuscular injections

Based on this trial design, predict the completion outcome and termination type (if applicable).